Mobile

A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dose o...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002783-10

A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dose of AS03, compared to a second dose of Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in subjects 18-60 years previously vaccinated in FLU-LD-004 clinical trial

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess during the entire study period (30 days) the safety and reactogenicity of re-vaccination with the low dose influenza vaccine adjuvanted with half dose of AS03. Fluarix™ will be used as reference

Critère d'inclusion

  • Re-vaccination against influenza in male and female subjects aged 18-60 years old

Liens